NR667 CEA FINAL EXAM
2026–2027
(100 QUESTIONS AND CORRECT ANSWERS)
ALREADY GRADED A+ | 100% VERIFIED
Chamberlain University | Nurse Practitioner Q&A
Key Domains:
FNP Capstone Practicum • Advanced Clinical Reasoning • Primary Care Management
Advanced Pharmacology • Health Promotion • Disease Prevention
Evidence-Based Practice • Patient Safety
Expert-Aligned Structure | Exam-Ready Format | FNP / AGNP Capstone
,Introduction
This structured NR667 CEA Final Exam format for 2026–2027 provides a complete 100-
question, high-yield Family Nurse Practitioner capstone self-assessment modeled precisely
after the Chamberlain University NR667 / APEA / AANP / ANCC FNP blueprint. It
emphasizes clinical judgment, primary care management, evidence-based practice,
advanced pharmacology, health promotion, disease prevention, and patient safety
principles critical to advanced nursing practice and successful FNP certification.
Answer Format: All correct answers appear in bold and cyan, accompanied by concise
rationales explaining safety/clinical reasoning, code adherence, scope of practice, and why
alternative options are less appropriate.
NR667 CEA Domain % Q#
Primary Care 30% 1-30
Management – Adult
Pediatrics / Adolescent 15% 31-45
Health
Women’s Health / 15% 46-60
Reproductive / OB
Geriatrics / Chronic Care 10% 61-70
Advanced Pharmacology 10% 71-80
Health Promotion / 10% 81-90
Disease Prevention /
Screening
Evidence-Based Practice / 10% 91-100
Leadership / Patient
Safety / Ethics / Scope
,1. A 62-year-old African American male, BP 156/96 x2 visits, no CKD/DM, BMI 31, 10-
yr ASCVD 12%. JNC-8 / AHA first-line FNP antihypertensive choice?
A. Lisinopril alone first in all
B. Thiazide-type diuretic or dihydropyridine CCB – chlorthalidone / amlodipine
C. Beta-blocker atenolol first
D. Clonidine first
E. Hydralazine PRN
Correct Answer: B. Thiazide-type diuretic or dihydropyridine CCB –
chlorthalidone / amlodipine
Rationale: HTN Black adults without CKD/HF: thiazide or CCB first-line per JNC-8 /
AHA, superior stroke reduction. ACE/ARB less effective monotherapy. Lifestyle DASH,
Na <1500mg, weight loss. Correct: Thiazide-type diuretic or dihydropyridine CCB –
chlorthalidone / amlodipine.
Domain: Primary Care – HTN | NR667 CEA | Chamberlain – FNP – ANCC/AANP-aligned
2. A 54-year-old T2DM, A1c 8.4% on metformin 2000mg daily max tolerated, BMI 34,
eGFR 78, no ASCVD/CKD/HF yet. FNP next evidence-based add-on?
A. NPH insulin BID first
B. GLP-1 receptor agonist – semaglutide – weight loss benefit
C. Sliding scale insulin only
D. Pioglitazone first in HF
E. Stop metformin
Correct Answer: B. GLP-1 receptor agonist – semaglutide – weight loss benefit
Rationale: A1c >target on metformin: add GLP-1 RA preferred obesity – weight loss,
cardio-renal benefit, low hypoglycemia. SGLT2 if ASCVD/HF/CKD. Avoid sliding scale
alone. Correct: GLP-1 receptor agonist – semaglutide – weight loss benefit.
Domain: Primary Care – Endocrine | NR667 CEA | Chamberlain – FNP – ANCC/AANP-aligned
3. A 48-year-old, LDL 168, 10-yr ASCVD 14.5%, DM negative, BP 128/78, smoker.
Statin intensity per ACC/AHA?
A. No statin
B. Moderate-intensity statin
C. High-intensity atorvastatin 40-80mg / rosuvastatin 20-40mg
D. Ezetimibe alone
E. Fibrate first
Correct Answer: C. High-intensity atorvastatin 40-80mg / rosuvastatin 20-40mg
Rationale: ASCVD risk ≥7.5-20% intermediate + risk enhancers (LDL ≥160, smoking)
→ moderate-high intensity, LDL ≥190 or DM 40-75 or ASCVD clinical → high-intensity.
, Shared decision. Correct: High-intensity atorvastatin 40-80mg / rosuvastatin 20-
40mg.
Domain: Primary Care – Prevention | NR667 CEA | Chamberlain – FNP – ANCC/AANP-aligned
4. A 68-year-old COPD GOLD E, FEV1 48%, 2 exacerbations/yr, smoker. FNP
maintenance inhaler and #1 intervention?
A. SABA alone + continue smoking
B. LAMA+LABA dual – tiotropium + formoterol – PLUS smoking cessation counseling
+ pharmacotherapy – most impactful
C. ICS monotherapy
D. Theophylline first
E. Oral prednisone daily
Correct Answer: B. LAMA+LABA dual – tiotropium + formoterol – PLUS smoking
cessation counseling + pharmacotherapy – most impactful
Rationale: COPD exacerbator GOLD E: LAMA+LABA first, triple if eos ≥300/asthma
overlap. #1 mortality/morbidity impact: smoking cessation + vaccines (flu,
pneumococcal, RSV, COVID, Tdap). Correct: LAMA+LABA dual – tiotropium +
formoterol – PLUS smoking cessation counseling + pharmacotherapy – most
impactful.
Domain: Primary Care – Pulm | NR667 CEA | Chamberlain – FNP – ANCC/AANP-aligned
5. A 26-year-old asthma, symptoms >2days/week night awakenings 2x/month, FEV1
82% predicted, +12% bronchodilator reversibility. FNP step therapy per GINA 2024?
A. SABA PRN alone
B. Low-dose ICS-formoterol – maintenance and reliever – Track 1
C. Oral steroids daily
D. LAMA alone
E. Theophylline
Correct Answer: B. Low-dose ICS-formoterol – maintenance and reliever – Track
1
Rationale: GINA Track 1 preferred: low-dose ICS-formoterol MART – reduces severe
exacerbations vs SABA alone – SABA-alone no longer recommended. Correct: Low-
dose ICS-formoterol – maintenance and reliever – Track 1.
Domain: Primary Care – Pulm | NR667 CEA | Chamberlain – FNP – ANCC/AANP-aligned
6. A 23-year-old healthy female acute dysuria, frequency, urgency, afebrile, no flank
pain, UA nitrite +, LE +. First-line FNP outpatient?
A. Ciprofloxacin 7 days
B. Nitrofurantoin 100mg BID x5 days
C. IV ceftriaxone
2026–2027
(100 QUESTIONS AND CORRECT ANSWERS)
ALREADY GRADED A+ | 100% VERIFIED
Chamberlain University | Nurse Practitioner Q&A
Key Domains:
FNP Capstone Practicum • Advanced Clinical Reasoning • Primary Care Management
Advanced Pharmacology • Health Promotion • Disease Prevention
Evidence-Based Practice • Patient Safety
Expert-Aligned Structure | Exam-Ready Format | FNP / AGNP Capstone
,Introduction
This structured NR667 CEA Final Exam format for 2026–2027 provides a complete 100-
question, high-yield Family Nurse Practitioner capstone self-assessment modeled precisely
after the Chamberlain University NR667 / APEA / AANP / ANCC FNP blueprint. It
emphasizes clinical judgment, primary care management, evidence-based practice,
advanced pharmacology, health promotion, disease prevention, and patient safety
principles critical to advanced nursing practice and successful FNP certification.
Answer Format: All correct answers appear in bold and cyan, accompanied by concise
rationales explaining safety/clinical reasoning, code adherence, scope of practice, and why
alternative options are less appropriate.
NR667 CEA Domain % Q#
Primary Care 30% 1-30
Management – Adult
Pediatrics / Adolescent 15% 31-45
Health
Women’s Health / 15% 46-60
Reproductive / OB
Geriatrics / Chronic Care 10% 61-70
Advanced Pharmacology 10% 71-80
Health Promotion / 10% 81-90
Disease Prevention /
Screening
Evidence-Based Practice / 10% 91-100
Leadership / Patient
Safety / Ethics / Scope
,1. A 62-year-old African American male, BP 156/96 x2 visits, no CKD/DM, BMI 31, 10-
yr ASCVD 12%. JNC-8 / AHA first-line FNP antihypertensive choice?
A. Lisinopril alone first in all
B. Thiazide-type diuretic or dihydropyridine CCB – chlorthalidone / amlodipine
C. Beta-blocker atenolol first
D. Clonidine first
E. Hydralazine PRN
Correct Answer: B. Thiazide-type diuretic or dihydropyridine CCB –
chlorthalidone / amlodipine
Rationale: HTN Black adults without CKD/HF: thiazide or CCB first-line per JNC-8 /
AHA, superior stroke reduction. ACE/ARB less effective monotherapy. Lifestyle DASH,
Na <1500mg, weight loss. Correct: Thiazide-type diuretic or dihydropyridine CCB –
chlorthalidone / amlodipine.
Domain: Primary Care – HTN | NR667 CEA | Chamberlain – FNP – ANCC/AANP-aligned
2. A 54-year-old T2DM, A1c 8.4% on metformin 2000mg daily max tolerated, BMI 34,
eGFR 78, no ASCVD/CKD/HF yet. FNP next evidence-based add-on?
A. NPH insulin BID first
B. GLP-1 receptor agonist – semaglutide – weight loss benefit
C. Sliding scale insulin only
D. Pioglitazone first in HF
E. Stop metformin
Correct Answer: B. GLP-1 receptor agonist – semaglutide – weight loss benefit
Rationale: A1c >target on metformin: add GLP-1 RA preferred obesity – weight loss,
cardio-renal benefit, low hypoglycemia. SGLT2 if ASCVD/HF/CKD. Avoid sliding scale
alone. Correct: GLP-1 receptor agonist – semaglutide – weight loss benefit.
Domain: Primary Care – Endocrine | NR667 CEA | Chamberlain – FNP – ANCC/AANP-aligned
3. A 48-year-old, LDL 168, 10-yr ASCVD 14.5%, DM negative, BP 128/78, smoker.
Statin intensity per ACC/AHA?
A. No statin
B. Moderate-intensity statin
C. High-intensity atorvastatin 40-80mg / rosuvastatin 20-40mg
D. Ezetimibe alone
E. Fibrate first
Correct Answer: C. High-intensity atorvastatin 40-80mg / rosuvastatin 20-40mg
Rationale: ASCVD risk ≥7.5-20% intermediate + risk enhancers (LDL ≥160, smoking)
→ moderate-high intensity, LDL ≥190 or DM 40-75 or ASCVD clinical → high-intensity.
, Shared decision. Correct: High-intensity atorvastatin 40-80mg / rosuvastatin 20-
40mg.
Domain: Primary Care – Prevention | NR667 CEA | Chamberlain – FNP – ANCC/AANP-aligned
4. A 68-year-old COPD GOLD E, FEV1 48%, 2 exacerbations/yr, smoker. FNP
maintenance inhaler and #1 intervention?
A. SABA alone + continue smoking
B. LAMA+LABA dual – tiotropium + formoterol – PLUS smoking cessation counseling
+ pharmacotherapy – most impactful
C. ICS monotherapy
D. Theophylline first
E. Oral prednisone daily
Correct Answer: B. LAMA+LABA dual – tiotropium + formoterol – PLUS smoking
cessation counseling + pharmacotherapy – most impactful
Rationale: COPD exacerbator GOLD E: LAMA+LABA first, triple if eos ≥300/asthma
overlap. #1 mortality/morbidity impact: smoking cessation + vaccines (flu,
pneumococcal, RSV, COVID, Tdap). Correct: LAMA+LABA dual – tiotropium +
formoterol – PLUS smoking cessation counseling + pharmacotherapy – most
impactful.
Domain: Primary Care – Pulm | NR667 CEA | Chamberlain – FNP – ANCC/AANP-aligned
5. A 26-year-old asthma, symptoms >2days/week night awakenings 2x/month, FEV1
82% predicted, +12% bronchodilator reversibility. FNP step therapy per GINA 2024?
A. SABA PRN alone
B. Low-dose ICS-formoterol – maintenance and reliever – Track 1
C. Oral steroids daily
D. LAMA alone
E. Theophylline
Correct Answer: B. Low-dose ICS-formoterol – maintenance and reliever – Track
1
Rationale: GINA Track 1 preferred: low-dose ICS-formoterol MART – reduces severe
exacerbations vs SABA alone – SABA-alone no longer recommended. Correct: Low-
dose ICS-formoterol – maintenance and reliever – Track 1.
Domain: Primary Care – Pulm | NR667 CEA | Chamberlain – FNP – ANCC/AANP-aligned
6. A 23-year-old healthy female acute dysuria, frequency, urgency, afebrile, no flank
pain, UA nitrite +, LE +. First-line FNP outpatient?
A. Ciprofloxacin 7 days
B. Nitrofurantoin 100mg BID x5 days
C. IV ceftriaxone
